References
- Montoto S, Lister T A. Secondary central nervous system lymphoma: risk factors and prophylaxis. Hematol Oncol Clin North Am 2005; 19: 751–763
- Gururangan S, Sposto R, Cairo M S, Meadows A T, Finlay J L. Outcome of CNS disease at diagnosis in disseminated small noncleaved-cell lymphoma and B-cell leukemia: a Children's Cancer Group study. J Clin Oncol 2000; 18: 2017–2025
- Hollender A, Kvaloy S, Lote K, Nome O, Holte H. Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis. Eur J Cancer 2000; 36: 1762–1768
- Mead G M, Bleehen N M, Gregor A, Bullimore J, Shirley D, Rampling R P, et al. A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer 2000; 89: 1359–1370
- O'Neill B P, O'Fallon J R, Earle J D, Colgan J P, Brown L D, Krigel R L. Primary central nervous system non-Hodgkin's lymphoma: survival advantages with combined initial therapy?. Int J Radiat Oncol Biol Phys 1995; 33: 663–673
- Schultz C, Scott C, Sherman W, Donahue B, Fields J, Murray K, et al. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06. J Clin Oncol 1996; 14: 556–564
- Skarin A T, Zuckerman K S, Pitman S W, Rosenthal D S, Moloney W, Frei E, III, et al. High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including CNS involvement. Blood 1977; 50: 1039–1047
- Abrey L E, Batchelor T T, Ferreri A J, Gospodarowicz M, Pulczynski E J, Zucca E, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005; 23: 5034–5043
- Cheson B D, Pfistner B, Juweid M E, Gascoyne R D, Specht L, Horning S J, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579–586
- Ferreri A J, Reni M, Zoldan M C, Terreni M R, Villa E. Importance of complete staging in non-Hodgkin's lymphoma presenting as a cerebral mass lesion. Cancer 1996; 77: 827–833
- O'Neill B P, Dinapoli R P, Kurtin P J, Habermann T M. Occult systemic non-Hodgkin's lymphoma (NHL) in patients initially diagnosed as primary central nervous system lymphoma (PCNSL): how much staging is enough?. J Neurooncol 1995; 25: 67–71
- Mohile N A, Deangelis L M, Abrey L E. The utility of body FDG PET in staging primary central nervous system lymphoma. Neuro Oncol 2008; 10: 223–228
- Iwamoto F M, DeAngelis L M, Abrey L E. Primary dural lymphomas: a clinicopathologic study of treatment and outcome in eight patients. Neurology 2006; 66: 1763–1765